Radical prostatectomy (RP) may be a treatment option for prostate cancer patients with cirrhosis and liver disease (CLD). However, the effect of CLD on adverse in-hospital outcomes after RP has not been well described.
Descriptive analyses, propensity score matching (PSM), and multivariable logistic and Poisson regression models were used to address National Inpatient Sample RP patients between 2005 and 2019. CLD severity was stratified as mild vs. moderate/severe.
Of 191,050 RP patients, 1,559 (0.8%) had CLD. Of those, 1,515 (97.2%) vs. 44 (2.8%) were classified as having mild and moderate/severe CLD, respectively. Any CLD rate increased from 0.6% to 1.5% (2005-2019, EAPC: +7.9%, P < 0.001). CLD patients exhibited higher rates of all 15 examined adverse in-hospital outcomes. The absolute differences were largest for overall complications (+13.9%), length of stay >2 days (+8.9%), and blood transfusions (+4.0%, all P < 0.001). After detailed multivariable adjustment, CLD independently predicted higher rates of all 15 adverse in-hospital outcomes (P < 0.01). The detrimental effect was most pronounced for in-hospital mortality (multivariable odds ratio (OR) 8.74), infectious complications (OR 4.59), and hepatic complications (OR 4.45). Finally, a convincing dose-response relationship, where the effect magnitude of moderate/severe CLD was at least 3 times higher than that of mild CLD, applied in 4 of 15 comparisons.
CLD patients exhibited higher rates of adverse in-hospital outcomes after RP. However, mild CLD did not exert a prohibitive effect that would clearly preclude RP as a treatment option.
Urologic oncology. 2025 Mar 08 [Epub ahead of print]
Fabian Falkenbach, Natali Rodriguez Peñaranda, Mattia Longoni, Andrea Marmiroli, Quynh Chi Le, Calogero Catanzaro, Michele Nicolazzini, Marie-Lyssa Lafontaine, Zhe Tian, Jordan A Goyal, Stefano Puliatti, Riccardo Schiavina, Carlotta Palumbo, Gennaro Musi, Felix K H Chun, Alberto Briganti, Fred Saad, Shahrokh F Shariat, Lars Budäus, Markus Graefen, Pierre I Karakiewicz
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg- Eppendorf, Hamburg, Germany. Electronic address: ., Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy., Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Division of Experimental Oncology, Unit of Urology, Vita-Salute San Raffaele University, Milan, Italy., Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy., Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany., Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Division of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy., Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy; Division of Urology, Department of Oncology, University of Turin, Orbassano, Italy., Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada., Department of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy., Division of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy., Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy., Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy., Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany., Division of Experimental Oncology, Unit of Urology, Vita-Salute San Raffaele University, Milan, Italy., Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan., Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg- Eppendorf, Hamburg, Germany; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.